Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

861
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
861
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

547
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
547
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

571
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
571
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

408
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
408
Hormonal Regulation01:33

Hormonal Regulation

30.3K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.3K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

681
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
681

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of the Pre-Eclampsia Integrated Estimate of Risk-Machine Learning (PIERS-ML) model in a Kenyan cohort of women with pre-eclampsia- a retrospective test derivation validation study.

BMC pregnancy and childbirth·2026
Same author

First Trimester Screening for Preterm Preeclampsia in the United Kingdom: A Cost-Effectiveness Analysis.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

10-Minute Consultation: Discussing and prescribing analgesia in pregnancy.

BMJ (Clinical research ed.)·2026
Same author

Perceptions of maternity care-seeking and care-giving experiences during a health-system shock: a qualitative study with healthcare professionals and policymakers in the UK, with a focus on care for marginalised groups.

BMJ public health·2026
Same author

Terminal Digit Preference and Threshold Avoidance in Digital Blood Pressure Measurements During Pregnancy: Secondary Analysis of Data From the CLIP and PRECISE Cohorts.

JMIR mHealth and uHealth·2026
Same author

Pre-eclampsia risk-stratified planned birth at term: A survey of women's perspectives on acceptability and risk communication.

Acta obstetricia et gynecologica Scandinavica·2026

Related Experiment Videos

Pre-eclampsia: an update.

Peter von Dadelszen1, Laura A Magee

  • 1Department of Obstetrics and Gynaecology, University of British Columbia, Rm V3-339, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada, pvd@cw.bc.ca.

Current Hypertension Reports
|June 12, 2014
PubMed
Summary
This summary is machine-generated.

Pre-eclampsia is a leading cause of maternal death, especially in developing nations. Antenatal surveillance, aspirin, calcium, and magnesium sulfate are key for prevention and management, reducing severe outcomes.

Related Experiment Videos

Area of Science:

  • Obstetrics and Gynecology
  • Maternal Health
  • Cardiovascular Disease in Pregnancy

Background:

  • Pre-eclampsia is the second leading cause of direct maternal mortality globally, disproportionately affecting less developed countries.
  • Significant reductions in UK maternal deaths from pre-eclampsia (1952-2008) were linked to antenatal surveillance and timely delivery.
  • Pre-eclampsia is a predictor of future cardiovascular disease in women.

Purpose of the Study:

  • To review the pathogenesis, diagnostic criteria, prediction models, prevention, and management of pre-eclampsia.
  • To highlight evidence-based strategies for preventing and managing pre-eclampsia and its complications.
  • To discuss the implications of pre-eclampsia for long-term maternal cardiovascular health.

Main Methods:

  • Review of existing literature on pre-eclampsia pathogenesis, diagnosis, prediction, prevention, and management.
  • Discussion of risk assessment tools like the Pre-eclampsia Integrated Estimate of RiSk (PIERS) models.
  • Analysis of evidence for interventions including aspirin, calcium, heparin, hypertension management, and magnesium sulfate.

Main Results:

  • Antenatal surveillance and timed delivery significantly reduced pre-eclampsia-related maternal deaths.
  • Low-dose aspirin (early initiation) and calcium are evidence-based preventative strategies for high-risk women.
  • Magnesium sulfate is effective for preventing and treating eclampsia; its role in non-severe hypertension management is guided by the CHIPS Trial.

Conclusions:

  • Effective management strategies, including surveillance and specific interventions, can mitigate severe pre-eclampsia complications.
  • Early identification and intervention are crucial for improving maternal outcomes.
  • Further research is needed to address the long-term cardiovascular risks associated with pre-eclampsia.